The data shown are the means of three independent cultures for each treatment condition and is presented as the fold change of the treated samples relative to the respective solvent/day 0 controls ± SEM; n = 3. The data shown are representative of three independent experiments. n.d: non-detectable.
Acetate: Supplementary Figure 3 | Acetate-and FFAR2/3 synthetic agonist-induced cytokine inhibition is dose-responsive. Human monocytes were treated with acetate, CFMB (FFAR2 agonist), AR420626 (FFAR3 agonist) or the respective solvent control for 15 min followed by a 4 h activation with 100 ng/mL LPS before the cytokine mRNA levels were measured by real-time PCR analysis. The data shown are the means of three independent cultures for each treatment condition and is presented as the fold change of the acetate/CFMB/AR420626 treated samples relative to the respective solvent controls ± SEM; n = 3. The data shown are representative of three independent experiments. n.d: non-detectable. The two tailed Welch's t-test was used to determine the statistical significance of the fold change (between the agonist treatment group and controls) and is annotated as: * < 0.05, ** < 0.005, and *** < 0.0005. Phos-p38
Total p38
Phos-p38
Total p38 NT PT + PT YM254890 YM254890
Supplementary Figure 6 | Acetate activates human monocyte p38 in a Gq/11 dependent manner. Phosphorylation of p38 by 5 mM acetate is abolished in human monocytes treated with YM254890 (Gq/11 inhibitor) alone or a combination of YM254890 and Pertussis toxin (PT, GiG0 inhibitor), but is retained in the solvent control (NT) monocytes and monocytes treated with PT alone. Cells were pretreated with PT for 2 h and/or YM254890 for 30 min before acetate induction. Each lane represents an independent culture for each treatment condition. The corresponding optical density (OD) is shown as the mean ± SEM; n = 3. The solvent controls (NT and 0.1% v/v DMSO) have been arbitrarily assigned the value of 1. The two tailed Welch's t-test was used to determine statistical significance and is annotated as: * < 0.05 and *** < 0.0005. The data shown are representative of three independent experiments. Human monocytes/macrophages were treated with 5 mM acetate or a solvent control (water) for 15 min followed by 100 ng/mL LPS. Real-time PCR analysis of cytokine mRNA. Acetate treatment failed to attenuate CCL2 expression in macrophages. Monocytes from the same donor prior to differentiation are shown as controls. The data shown are the means of three independent cultures for each treatment condition and are presented as the fold change of the acetate/synthetic agonist treated samples relative to the respective solvent controls ± SEM; n = 3. The data shown are representative of three independent experiments. n.d: non-detectable. The two tailed Welch's t-test was used to determine the statistical significance of the fold change (between the agonist treatment group and controls) and is annotated as: * < 0.05, ** < 0.005, and *** < 0.0005. (c) P38 phosphorylation in human macrophages during 5 mM acetate treatment. (d) Western blot of human macrophages treated with 5 mM acetate for 15 min followed by 100 ng/mL LPS challenge. Mouse monocytes treated with the indicated concentrations of agonists or solvent controls for 15 min followed by challenge with 100 ng/mL LPS for the indicated times. When not indicated, 5 mM acetate and 10 M FFAR3 agonist (AR420626) was used, respectively. Cytokine mRNA levels were determined through real-time PCR analysis. The data shown is the mean of three independent cultures for each treatment condition and is presented as the fold change of the acetate or synthetic agonist treated samples relative to the respective solvent controls ± SEM; n = 3. The data shown are representative of three independent experiments. The two tailed Welch's t-test was used to determine the statistical significance of the fold change (between the agonist treatment group and controls) and is annotated as: * < 0.05, ** < 0.005, and *** < 0.0005. 
